Four Alzheimer’s patients treated with an immune system therapy have seen their disease stabilize for at least three years, raising hope that the drug from Baxter International Inc will prove effective in larger trials. Scientists say the study released on Tuesday is too small to show whether the drug will ultimately prove effective, but any sign of progress in Alzheimer’s research is welcome. Scientists expect Baxter’s results next year. “Over the last few years there have been a lot of conspicuous failures with Alzheimer’s drugs,” said Dr. Norman Relkin of Weill Cornell Medical College in New York. Relkin presented three-year results on Baxter’s study at the Alzheimer’s Association International Conference in Vancouver.
